Carnitine for fatigue in multiple sclerosis

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2008, Pages

  Tejani, Aaron ^a   Spiwak, Rae ^b   Wasdell, Michael ^b   Rowell, Greg ^b   Nathwani, Shabita ^c  

^a FRASER HEALTH AUTHORITY   (Canada)

^b Burnaby Hospital   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMINOPYRIDINE; CARNITINE; HISTAMINE DERIVATIVE; MODAFINIL; PEMOLINE; PLACEBO; PROKARIN; UNCLASSIFIED DRUG;

AEROBIC EXERCISE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; GENERAL CONDITION IMPROVEMENT; HUMAN; METHODOLOGY; MORTALITY; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PARALLEL DESIGN; QUALITY OF LIFE; REVIEW; SUPPLEMENTATION; SYMPTOM; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 55049139949     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007280     Document Type: Review

References (43)

1. Branas 2000 Branas P, Jordan RE, Fry-Smith A, Burls A, Hyde CJ. Treatments for fatigue in multiple sclerosis: a rapid and systematic review. Health Technology Assessment 2000;4:27.
2. Ciacci 2007 Ciacci C, Peluso G, Iannoni E, Sinisgalchi M, Iovino P, Rispo A, et al.L-Carnitine in the treatment of fatigue in adult celiac disease patients: a pilot study. Digestive Liver Disease 2007;39(10):922-8.
3. Cruciani 2004 Cruciani RA, Dvorkin E, Homel P, Culliney B, Malamud S, Shaiova L, et al.L-carnitine supplementation for the treatment of fatigue and depressed mood in cancer patients with carnitine deficiency: a preliminary analysis. Annals of the New York Academy of Sciences 2004;1033: 168-76.
4. Cylert Insert Cylert (package insert). Abbott Laboratories: East Chicago, Illinois 1999.
5. Fisk 1994 Fisk JD, Pontefract A, Ritvo PG, Archibald CJ, Murray TJ. The impact of fatigue on patients with multiple sclerosis.. Canadian Journal of Neurological Sciences 1994;21:9-14.
6. Flensner 2002 Flensner G, Lindencrona C. The cooling-suit: case studies of its influence on fatigue among eight individuals with multiple sclerosis. Journal of Advanced Nursing 2002;37:541-50.
7. Freal 1985 Freal JE, Kraft GH, Coryell JK. Symptomatic fatigue in multiple sclerosis. Archives of Physical Medicine and Rehabilitation 1984;65:135-8.
8. Gillson 2002 Gillson G, Richard TL, Smith RB, Wright JV. A double-blind pilot study of the effect of Prokarin on fatigue inmultiple sclerosis. Multiple Sclerosis 2002;8:30-5.
9. Graziano 2002 Graziano F, Bisonni R, Catalano V, Silva R, Rovidati S, Mencarini E, et al.Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. British Journal of Cancer 2002;86:1854-7.
10. Helman 2005 Helman A. Carnitine for Alzheimer's Disease. Arbor Clinical Nutrition Updates 2005;230:1-2.
11. Iriarte 1999 Iriarte J, Katsamakis G, de Castro P. The fatigue descriptive scale (FDS): a useful tool to evaluate fatigue in multiple sclerosis. Multiple Sclerosis 1999;5:10-16.
12. Jackson 1991 Jackson MF, Quaal C, Reeves MA. Effects of multiple sclerosis on occupational and career patterns multiple sclerosis on occupational and career patterns. Axone 1991;13:16-17.
13. Janardhan 2002 Janardhan V, Bakshi R. Quality of life in patients with multiple sclerosis: the impact of fatigue and depression. Journal of Neurological Sciences 2002;205:51-8.
14. Kos 2007 Kos D, Kerckhofs E, Nagels G, D'hooghe MB, Llsbroukx S. Origin of Fatigue in Multiple Sclerosis: Review of the Literature. Neurorehabilitation and Neural Repair (2007): 1545968306298934 (accessed October 10 2007).
15. Krupp 1988 Krupp LB, Alvarez LA, LaRocca NG, Scheinberg LC. Fatigue in multiple sclerosis.. Archives of Neurology 1988;45:435-7.
16. Krupp 1995 Krupp LB, Coyle PK, Doscher C, Miller A, Cross AH, Jandorf L, et al.Fatigue therapy inmultiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology 1995;45:1956-61.
17. Laviano 2006 Laviano A, Mequid MM, Guijarro A, Muscaritoli M, Cascino A, Preziosa I, et al.Antimyopathic Effects of Carnitine and Nicotine. Current Opinion in Clinical Nutrition and Metabolic Care 2006;9(4):442-8.
18. Lazoff 2005 Lazoff M. Multiple Sclerosis. www.emedicine.com (accessed 16 October 2007).
19. Lebrun 2006 Lebrun C, Alchaar H, Candito M, Bourg V, Chatel M. Levocarnitine administration inmultiple sclerosis patients with immunosuppressive therapy-induced fatigue. Multiple Sclerosis 2006;12:321-4.
20. Malaguarnera 2007 Malaguarnera M, Callamerri L, Gargante MP, Vacante M, Colonna V, Motta M. L-Carnitine treatment reduces severity of physical and mental fatigue and increases cognitive functions in centenarians: a randomized and controlled clinical trial. American Journal of Clinical Nutrition 2007;86:1738-44.
21. Marthaler 1999 Marthaler NP, Visarius T, Kupfer A, Lauterburg BH. Increased urinary losses of carnitine during ifosfamide chemotherapy. Cancer Chemotherapy Pharmacology 1999;44:170-2.
22. McDonald 2001 McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al.Recommended Diagnostic Criteria for Multiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Annals of Neurology 2001;50(1):121-7.
23. Mostert 2002 Mostert S, Kesselring J. Effects of a short-term exercise training program on aerobic fitness, fatigue, health perception and activity level of subjects with multiple sclerosis. Multiple Sclerosis 2002;8:161-8.
24. Murray 1985 Murray TJ. Amantadine therapy for fatigue in multiple sclerosis. Canadian Journal of Neurological Sciences 1985;12:251- 4.
25. Peluso 2000 Peluso G, Nicolai R, Reda E, Benatti P, Barbarisi A, Calvani M. Cancer and anticancer therapy-induced modifications on metabolism mediated by carnitine system. Journal of Cell Physiology 2000;182:339-50.
26. Pistone 2003 Pistone G, Marino AD, Leotta C, Dell'Arte S, Finocchario G, Malaguarnera M. Levocarnitine administration in elderly subjects with rapid muscle fatigue. Drugs Aging 2003;20:761-7.
27. Plioplys 1997 Plioplys AV, Plioplys S. Amantadine and L-carnitine treatment of chronic fatigue syndrome. Neuropsychobiology 1997;35:16-23.
28. Polman 2005 Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al.Diagnostic Criteria for Multiple Sclerosis: 2005 revisions to the Macdonald Criteria. Annals of Neurology 2005;59(4):840-6.
29. Poser 1983 Poser CM, Paty DW, Scheinberg L, Mc Donald WI, Davis FA, Ebers GC, et al.New diagnostic criteria for Multiple Sclerosis: guide-lines for research protocols. Annals of Neurology 1983;13(3):227-31.
30. Pucci 2007 Pucci E, Branas P, D'Amico R, Giuliani G, Solari A, Taus C. Amantadine for fatigue in multiple sclerosis. Cochrane Database of Systematic Reviews 2007, Issue 1.[Art. No.: CD002818. DOI: 10.1002/14651858.CD002818.pub2]
31. PVA 1998 Multiple Sclerosis Council for Clinical Practice Guidelines. Fatigue and Multiple Sclerosis: Evidence-Based Management Strategies for Fatigue in Multiple Sclerosis. Paralyzed Veterans of America 1998.
32. Racke 2004 Racke MK, Hawker K, Frohman EM. Fatigue in Multiple Sclerosis: is the picture getting simpler or more complex?. Archives of Neurology 2004;61:176-7.
33. Rammohan 2002 Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two-centre phase 2 study. Journal of Neurologu, Neurosurgery and Psychiatry 2002;72:179-83.
34. Rossini 2007 Rossini M, Di Munno O, Valentini G, Bianchi G, Cacace E, et al.Double-blind, multicenter trial comparing acetyl l-carnitine with placebo in the treatment of fibromyalgia patients. Clinical and Experimental Rheumatology 2007;25(2):182-8.
35. Sayed-Ahmed 1999 Sayed-Ahmed MM, Shaarawy S, Shouman SA, Osman AMM. Reversal of doxorubicin-induced cardiac metabolic damage by L-carnitine. Pharmacological Research 1999;39:289-95.
36. Schumacher 1965 Schumacher GA, Beebe G, Kibler RF, Kurland LT, Kurtzke JF, McDowell, et al.Problems of experimental trials of therapy in Multiple Sclerosis: Report by the panel of the evaluation of experimental trials in Multiple Sclerosis.. Annals of the New York Academy of Sciences 1965;122:552-68.
37. Schwid 2002 Schwid S, Covington M, Segal B, Goodman A. Fatigue in multiple sclerosis: Current understanding and future direction. Journal of rehabilitation Research and Development 2002;39:211-24.
38. Solari 2002 Solari A, Uitdehaag B, Giuliani G, Pucci E, Taus C. Aminopyridines for symptomatic treatment in multiple sclerosis. Cochrane Database of Systematic Reviews 2002, Issue 4.[Art. No.: CD001330. DOI: 10.1002/14651858.CD001330]
39. Tellez 2006 Tellez N, Rio J, Tintore M, Nos C, Galan I, Montalban X. Fatigue in Multiple Sclerosis Persists Over Time : a longitudinal study.. Journal of Neurology 2006;253:1466-70.
40. Tomassini 2004 Tomassini V, Pozzilli C, Onesti E, Pasqualetti P, Marinelli F, Pisani A, et al.Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. Journal of Neurological Sciences 2004;218(1-2):103-8.
41. UK MS 1997 United Kingdom Multiple Sclerosis Society. Symptom Management Survey. United Kingdom Multiple Sclerosis Society.
42. Weinshenker 1992 Weinshenker BG, Penman M, Bass B, Ebers GC, Rice GPA. A double-blind, randomized crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology 1992;42:1468-71.
43. Zifko 2002 Zifko UA, Rupp M, Schwarz S, Zipko HT, Maida EM. Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. Journal of Neurology 2002;249:983-7.